Cyclosporine: The case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets

被引：9

作者：

Barr, WH ^{[1
]}

机构：

[1] Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA 23219 USA

来源：

TRANSPLANTATION PROCEEDINGS | 1999年 / 31卷 / 3A期

关键词：

D O I：

10.1016/S0041-1345(99)00110-4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：25S / 30S

页数：6

共 21 条

[1]

BARR WH, 1997, SCI FDN REGULATING D

[2] CALCINEURIN ACTIVITY IS ONLY PARTIALLY INHIBITED IN LEUKOCYTES OF CYCLOSPORINE-TREATED PATIENTS [J].

BATIUK, TD ;

PAZDERKA, F ;

HALLORAN, PF .

TRANSPLANTATION, 1995, 59 (10) :1400-1404

[3]

CARTER BL, 1993, PHARMACOTHERAPY, V13, P359

[4]

CHOC GM, 1997, SCI FDN REGULATING D

[5]

Cooney GF, 1996, TRANSPLANT P, V28, P2270

[6]

CURTIS JJ, 1998, TRANSPLANTATION, V65, P141

[7] THE ABSORPTION SITE OF CYCLOSPORINE IN THE HUMAN GASTROINTESTINAL-TRACT [J].

DREWE, J ;

BEGLINGER, C ;

KISSEL, T .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (01) :39-43

[8] BIOINEQUIVALENCE AND DRUG TOXICITY - HOW GREAT IS THE PROBLEM AND WHAT CAN BE DONE [J].

GLEITER, CH ;

GUNDERTREMY, U .

DRUG SAFETY, 1994, 11 (01) :1-6

[9]

GRANT D, IN PRESS TRANSPLANTA

[10] A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation [J].

Hemming, AW ;

Greig, PD ;

Cattral, MS ;

Chung, SW ;

Lilly, LB ;

Aljumah, AA ;

Levy, GA .

TRANSPLANTATION, 1996, 62 (12) :1798-1802

← 1 2 3 →